Genzyme on Wednesday announced data from a late-stage study demonstrating that Clolar used in combination with cytarabine did not improve overall survival in patients with relapsed-refractory adult acute myeloid leukemia compared to cytarabine alone. However, the Clolar combination demonstrated statistical significance in the secondary endpoints of overall remission rates, complete remission rates; event-free survival; and four-month event free survival. Full results from the Classic I trial will be presented at an upcoming medical meeting, Genzyme noted.
Reference Articles
Genzyme leukemia drug fails to extend survival - (Fidelity)
Genzyme announces results of Phase 3 trial of Clolar in adult AML - (Genzyme)
Genzyme's Clolar fails late-stage leukemia study - (MSN Money)
Genzyme's leukemia drug Clolar misses primary goal in combination study - (Stock Markets Review)
**Published in "First Word"
No comments:
Post a Comment